TBPH Files 8-K for 'Other Events' and Financial Exhibits
Ticker: TBPH · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 8-K |
| Filed Date | Jan 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-filing, other-events, financial-disclosure
TL;DR
**TBPH just dropped an 8-K, check for new info on 'Other Events' and financials.**
AI Summary
Theravance Biopharma, Inc. (TBPH) filed an 8-K on January 5, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the company is providing additional information to the public, potentially related to a significant development or a required disclosure. For investors, this matters because it signals that new, potentially impactful information about the company's operations or financial health has been released, which could influence stock performance.
Why It Matters
This filing indicates that Theravance Biopharma is disclosing new information, which could be a material event affecting its business or financial outlook. Investors should review the full filing to understand the specific details and potential impact on the company's valuation.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the unspecified 'Other Events' could carry significant risk or opportunity depending on the disclosed content.
Analyst Insight
A smart investor would immediately access the full 8-K filing to understand the specific 'Other Events' and 'Financial Statements and Exhibits' disclosed, as these could contain material information impacting the stock price.
Key Numbers
- 001-36033 — Commission File Number (identifies the company's registration with the SEC)
- 98-1226628 — I.R.S. Employer Identification Number (identifies the company for tax purposes)
- KY1-1104 — Zip Code (part of the company's principal executive offices address)
- 650-808-6000 — Business Phone Number (contact information for the company)
Key Players & Entities
- Theravance Biopharma, Inc. (company) — the registrant filing the 8-K
- NASDAQ Global Market (company) — the exchange where TBPH's Ordinary Shares are registered
- January 5, 2024 (date) — the date of the earliest event reported and the filing date
- 001-36033 (dollar_amount) — Commission File Number
Forward-Looking Statements
- The full content of the 8-K will reveal a significant corporate action or financial update. (Theravance Biopharma, Inc.) — medium confidence, target: Q1 2024
FAQ
What is the primary purpose of this 8-K filing by Theravance Biopharma, Inc.?
The primary purpose of this 8-K filing, dated January 5, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits' as per Item Information sections.
Where are Theravance Biopharma, Inc.'s principal executive offices located?
Theravance Biopharma, Inc.'s principal executive offices are located at PO Box 309 Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands, KY1-1104.
On which stock exchange are Theravance Biopharma, Inc.'s Ordinary Shares registered?
Theravance Biopharma, Inc.'s Ordinary Shares, with a $0.00001 Par Value, are registered on the NASDAQ Global Market under the trading symbol TBPH.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 5, 2024.
What is the state or other jurisdiction of incorporation for Theravance Biopharma, Inc.?
Theravance Biopharma, Inc. is incorporated in the Cayman Islands.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-05 06:07:26
Key Financial Figures
- $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Market
Filing Documents
- tm242154d1_8k.htm (8-K) — 24KB
- tm242154d1_ex99-1.htm (EX-99.1) — 40KB
- tm242154d1_ex99-1img01.jpg (GRAPHIC) — 3KB
- 0001104659-24-001556.txt ( ) — 245KB
- tbph-20240105_lab.xml (EX-101.LAB) — 33KB
- tbph-20240105_pre.xml (EX-101.PRE) — 22KB
- tbph-20240105.xsd (EX-101.SCH) — 3KB
- tm242154d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. On January 5, 2024, Theravance Biopharma, Inc. issued a press release to announce results from the Phase 4 PIFR-2 study of YUPELRI (revefenacin) inhalation solution. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated January 5, 2024 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: January 5, 2024 By: /s/ Brett Grimaud Brett Grimaud General Counsel